Circulating metabolites associated with tumor hypoxia and early response to treatment in bevacizumab-refractory glioblastoma after combined bevacizumab and evofosfamide

Circulating metabolites associated with tumor hypoxia and early response to treatment in bevacizumab-refractory glioblastoma after combined bevacizumab and evofosfamide

Glioblastomas (GBM) are the most common and aggressive form of primary malignant brain tumor in the adult population, and, despite modern therapies, patients often develop recurrent disease, and the disease remains incurable with median survival below 2 years. Resistance to bevacizumab is driven by...

Full description

Bibliographic Details
Main Authors: Alessia Lodi, Renu Pandey, Jennifer Chiou, Ayon Bhattacharya, Shiliang Huang, Xingxin Pan, Brandon Burgman, S. Stephen Yi, Stefano Tiziani, Andrew J. Brenner
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-09-01
Series:Frontiers in Oncology
Subjects:
glioblastoma (GBM)
bevacizumab (BEV)
evofosfamide (TH-302)
metabolomics (OMICS)
circulating metabolites
enantiomers
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.900082/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.900082/full

Similar Items